secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2026-10-07T12:30:40+00:00
Accession:  0001213900-26-107410
Event type: m_and_a
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

CERo Therapeutics to sell operating subsidiary to SRX Global for $1M stock plus forgiveness of $8.25M secured note
--------------------------------------------------------------------------------

- Holdings to sell all stock of unit CERo Therapeutics, Inc. to SRX Global Inc. under an October 6, 2026 Stock Purchase Agreement; lead candidate CER-1236 goes with the subsidiary.
- Consideration: SRX shares worth $1,000,000 (computed at the lower of SRX's pre-signing close or 20-day VWAP) plus cancellation of the $8,249,643.77 Consolidated Note balance.
- Buyer also assumes approximately $1,562,000 of specified liabilities; Consolidated Note maturity extended to 5 business days after Closing or valid termination.
- 30-day go-shop runs from signing with Joseph Gunnar & Co. retained; a Superior Proposal gets up to 45 extra days and must close by March 15, 2027; $750,000 termination fee each way.
- Closing conditioned on SRX acquiring Holdings' Series C, D and E preferred and Series A holders waiving or converting; no common stockholder vote needed under DGCL Section 272 collateral sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390026107410/0001213900-26-107410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390026107410/ea0307733-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-107410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer